Labcorp isn’t alone in developing alternatives to the more invasive cerebrospinal fluid tests and expensive PET brain scans currently used to spot the biological changes associated with Alzheimer’s ...

Labcorp Holdings, Inc. LH has announced the nationwide availability of the Lumipulse pTau-217/Beta Amyloid 42 Ratio — the first FDA-cleared blood-based in-vitro diagnostic (IVD) test to assist in ...

BURLINGTON, N.C., Feb. 11, 2026 /PRNewswire/ -- Labcorp (LH), a global leader of innovative and comprehensive laboratory services, announced today the nationwide availability of the Elecsys® pTau-181 ...

Add Yahoo as a preferred source to see more of our stories on Google. FILE PHOTO: The logo for Labcorp is displayed on a screen on the floor of the NYSE in New York By Deena Beasley (Reuters) - ...

The nationwide rollout, which Labcorp disclosed Monday, comes weeks after the Centers for Medicare and Medicaid Services approved coverage for ColoSense, and the American Cancer Society named the test ...

Labcorp's test combines readings of two blood-based proteins with measurements of mean arterial pressure and uterine artery pulsatility index. (Getty Images) Labcorp has begun rolling out a new blood ...

Please provide your email address to receive an email when new articles are posted on . Labcorp Diagnostics announced the launch of the first widely accessible blood test that provides direct evidence ...

Labcorp Holdings said it would soon offer a blood test for diagnosing Alzheimer's disease in primary-care settings. The Burlington, N.C., lab-services company on Thursday said the Elecsys pTau181 test ...

Labcorp introduced the first FDA-cleared blood test to aid in diagnosing Alzheimer's disease. LH's Lumipulse test delivers results comparable to CSF and PET scans with a simple blood draw. LH's launch ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min As the number of Americans at ...

(RTTNews) - Labcorp (LH) Wednesday has introduced the pTau-217/Beta Amyloid 42 Ratio test, a blood-based biomarker designed to aid in Alzheimer's diagnosis. Offering accuracy comparable to PET imaging ...